CoreAge Rx Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

A familiar medication name is not enough to establish what a telehealth purchase delivers. With CoreAge Rx, the evidence question starts with the particular compounded preparation, the clinician responsible for prescribing it and the pharmacy that will fill it. The company advertises semaglutide from $79 per month and tirzepatide from $129 per month, subject to clinical review. Those offers document a commercial service; they do not establish that its preparations reproduce the outcomes of published trials.

Public documentation consulted October 19, 2026, provides meaningful detail about intake, professional responsibilities, shipping and cancellation. It also contains consequential disagreements: whether an unsuccessful evaluation produces a full refund, when payment occurs, whether renewals are automatic and whether patients can choose a pharmacy. This review separates provider statements from clinical evidence and identifies what a prospective patient can reasonably establish before paying. Professional and pharmacy claims remain the company’s representations, not independently verified credentials.

At a glance

Documented offering: CoreAge Rx describes a U.S. telehealth service coordinating compounded semaglutide and tirzepatide; the advertised starting prices are $79 and $129 per month, respectively.
Sources: [14] [11]
Clinical responsibility: The legal footer assigns medical services to three independent professional entities and describes CoreAgeRx as a technology and administrative platform.
Sources: [11]
Refund conflict: The FAQ promises a 100% refund if a prescription is not approved; the refund policy retains an applicable $50–$100 consultation fee.
Sources: [7] [5]
Pharmacy uncertainty: The FAQ requires affiliated pharmacies, while the terms allow requesting a pharmacy of the patient’s choosing before completing an order.
Sources: [7] [12]
Evidence boundary: Compounded preparations are not FDA approved. FDA recommends them when an individual’s medical needs cannot be met by an approved drug; nonapproval alone does not establish clinical inequivalence.
Sources: [1]

Start with the product, not the trial headline

CoreAge Rx identifies its main offerings as compounded semaglutide and tirzepatide. Its semaglutide safety page describes subcutaneous injection and explicitly acknowledges that compounded formulations are not FDA approved or reviewed before dispensing for safety, effectiveness or manufacturing quality. That disclosure is important: approval belongs to a specific drug product, not to a telehealth platform or pharmacy. It neither establishes that CoreAge Rx’s preparations are clinically equivalent to approved products nor proves that they are inequivalent.

Published semaglutide and tirzepatide trials do not establish outcomes for this company’s compounded preparations. The distinction is especially relevant because the site also markets “Semaglutide Microdosing Therapy” from $79 per month and “Tirzepatide Microdosing Therapy” from $129 per month, the latter described as customized metabolic support. Those names and prices establish advertised offerings, not demonstrated longevity benefits or validation of a particular microdosing protocol. Our explanation of why trials are not provider performance reports develops that distinction.

Formulation also matters. The FAQ says compounded tirzepatide is typically formulated with B-12; someone preferring a version without B-12 can raise that during intake and discuss it with the provider. Availability is therefore not an unconditional patient choice. Separately, the company labels GLP-1 Support a dietary supplement, not a prescription medication. Readers should keep those categories separate rather than treating every GLP-1-branded item on the site as the same treatment.

Sources: [14] [8] [9] [7] [10] [6] [1] [3] [4]

Who actually provides the medical care?

The legal footer makes a distinction that the brand name alone can obscure. DSO Fine Shrimp, doing business as CoreAgeRx, provides the technology platform and administrative coordination. It states that it does not practice medicine, employ healthcare providers or participate in clinical decisions. Evaluations, treatment planning and prescribing are assigned exclusively to M & D Integrations Inc d/b/a MD Integrations, MDI Medical Group P.C., and MD Integrations & Wellness Provider Group P.A., described as independently owned and operated.

The product page says doctors review intake answers and that prescriptions are overseen by fully licensed and insured physicians. Elsewhere, the homepage refers more broadly to U.S.-licensed clinicians. These are provider representations, not the result of an independent licensing check. The useful next step is to identify the actual treating professional and professional entity assigned to the patient, rather than assuming that every person available through the platform has the same credentials or responsibility.

The policy identifies DSO Fine Shrimp LLC dba CoreAge Rx at 1309 Coffeen Avenue, Suite 1200, Sheridan, Wyoming 82801. That is a published contact address, not evidence that a particular consultation or pharmacy operation occurs there. The distinction illustrates what public provider documentation can establish: legal roles and contact information are documentable, while verified credentials, clinical performance and the quality of an individual encounter require different evidence.

Sources: [11] [5] [13]

What the advertised monthly prices establish

The homepage advertises compounded semaglutide from $79 per month and compounded tirzepatide from $129 per month, with the same price at every dose, supplies included and free shipping. Another homepage block advertises the two medicines collectively from $99 per month. That inconsistency does not erase the specific offers, but it makes a checkout-level explanation necessary. The consulted documentation does not establish the supply quantity, presentation or purchase conditions required to obtain each minimum, or the final amount collected.

The semaglutide page advertises no membership fees and no long-term contracts. The help center goes further, stating that the price becomes permanently fixed after purchase and does not increase with dose changes. Those are commercial promises to confirm against the selected order, not independently established guarantees. A monthly headline does not by itself identify the billing interval, quantity dispensed or minimum commitment, and it should not be converted into an assumed annual cost.

CoreAge Rx says it does not accept health insurance. Its terms also say the services are not insurance and that purchasers agree not to submit telemedicine-service claims to Medicare or other federal, state or private payers. That wording is more specific than a simple cash-pay label. The refund policy mentions Klarna and Affirm, but the consulted pages do not establish financing costs or terms. No documented basis supports assuming financing is interest-free or equivalent to paying directly.

Material differences to resolve before payment
Issue	Documented statements	What to confirm
Starting price	Semaglutide from $79/month; a general GLP-1 block says from $99/month.	Which offer applies, its presentation and quantity, and the full checkout charge.
Unsuccessful evaluation	FAQ promises a 100% refund; policy retains an applicable $50–$100 consultation fee.	The exact refundable amount for the selected order.
Charge timing	FAQ describes payment before review and billing when medication ships.	When a payment is collected and what it covers.
Renewals	FAQ says no auto-rebills; help center allows optional recurring subscriptions.	Whether checkout creates a one-time order or recurring authorization.
Pharmacy choice	FAQ requires the affiliated network; terms permit a pharmacy request before ordering.	Whether an outside pharmacy is available for this prescription.

Sources: [11] [13] [14] [7] [12] [5]

Intake is a clinical review, not an approval guarantee

The documented process begins with a confidential online health questionnaire. The FAQ estimates feedback from a doctor within approximately 24 hours, while noting that some states require video consultation or live chat. The help center says a telephone consultation is not required unless requested. Read together, these statements support an online-first process, not a universal promise that every patient can complete evaluation solely through a questionnaire or receive an approved prescription within one day.

The documentation policy allows requests for health history, current medicines, valid photo identification, patient photographs, laboratory results, medical records, primary-care documentation and answers to provider questions, depending on treatment. This matters because an apparently simple checkout may precede additional clinical work. The consulted materials do not establish a universal laboratory requirement or specific BMI and comorbidity criteria for each offering. The provider’s compounded-semaglutide safety page does specify exclusions: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a serious allergic reaction to semaglutide or ingredients in the formulation, and pregnancy or planned pregnancy. These are stated restrictions for that offering, not a complete eligibility assessment or established criteria for every product. Missing public criteria should not be interpreted as either automatic eligibility or the absence of screening.

The FAQ limits care to adults 18 and older and to the United States, with restrictions varying by state, therapy and medication and confirmed during intake. It does not provide an exhaustive medication-by-state availability list. For clinical preparation, NIDDK recommends discussing medicines, supplements, allergies and pregnancy plans with the treating clinician. That is a framework for an informed consultation, not a way to determine personal eligibility from this review or substitute for CoreAge Rx’s actual assessment.

Sources: [13] [7] [14] [5] [2] [10]

The pharmacy and formulation remain order-specific

The FAQ says prescriptions must currently be filled through CoreAge Rx’s affiliated pharmacy network and cannot use a local pharmacy. The terms, however, say patients can direct a prescription to a pharmacy of their choosing by emailing support before completing the order. These are materially different instructions. Neither should be silently discarded. Anyone for whom pharmacy choice matters needs written clarification for the specific treatment before purchase, including whether the advertised package remains available through that channel.

The FAQ does not identify a single dispensing pharmacy for all patients. Instead, it says assignment depends on the therapy and medication and directs readers to support to learn which pharmacy will fill the prescription. The semaglutide page advertises U.S. compounding, but that does not independently identify or verify the facility preparing an individual order. Dispensing and compounding are distinct responsibilities; a useful inquiry asks who performs each, along with the precise formulation and presentation being supplied.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a categorical legal conclusion about CoreAge Rx. It does make the clinical reason for a compounded preparation a substantive discussion, rather than merely a price comparison. Our guide to approved products and compounded preparations explains why shared ingredient names do not answer every product-specific evidence question.

Sources: [13] [7] [12] [1]

Refund and renewal language needs reconciliation

The FAQ explains that payment before medical review secures pricing and a place in the pharmacy queue, promising an automatic 100% refund if the prescription is not approved. Yet that same FAQ also says medication is billed when shipped. The refund policy introduces a further qualification: for medical ineligibility, the refundable treatment or medication portion is returned, while an applicable $50–$100 consultation fee remains nonrefundable. A prospective patient cannot resolve these differences simply by relying on the most favorable sentence.

Cancellation also has separate meanings. The help center offers a one-time purchase or optional subscription, while the FAQ says there are no automatic rebills. The policy permits subscription cancellation through the patient account or Patient Care Team to prevent future renewal charges; it must occur before the relevant renewal is processed. That does not automatically cancel an existing order. Order cancellation requires that prescription approval and pharmacy transmission have not occurred and that the order has not otherwise become nonrefundable.

Under the policy, prescription sales become final after provider approval and transmission to the pharmacy—even before shipment. It also makes orders nonrefundable 30 calendar days after purchase, even if incomplete or unshipped, except where applicable law requires otherwise. Approved refunds are generally processed within 5–10 business days, with additional bank time possible; financed refunds go through the financing provider. These are material limits, not evidence of when money will reach a patient’s bank account.

Sources: [14] [7] [5]

Delivery estimates do not establish cold-chain performance

The policy estimates order completion in approximately 5–7 business days when required information is submitted promptly, while acknowledging variability. It separately estimates arrival approximately 2–3 business days after the pharmacy ships. Those are different stages, not interchangeable delivery promises. Medical review, documentation, approval and pharmacy preparation occur before dispatch, so a roughly 24-hour clinical response does not imply medication arrival the next day. Nor does the documentation establish a guaranteed purchase-to-door deadline.

Standard prescription shipping is included unless checkout states otherwise, using USPS, UPS, FedEx or another designated carrier. Tracking follows by email, and the FAQ says no signature is required. For loss or damage, the policy asks patients to contact the Patient Care Team promptly; after review, CoreAge Rx will coordinate an appropriate replacement or reshipment when applicable. This is a conditional resolution process, not an unconditional promise to replace every disputed package or issue a refund.

The consulted documentation does not precisely establish refrigerated packaging, transit temperature monitoring or procedures for temperature excursions. FDA explicitly advises not using injectable GLP-1 medication that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. That advice should not be replaced by an assumption that free or fast shipping establishes temperature control. Before dispatch, a useful practical question is whom to contact about a questionable delivery and how quickly the pharmacy can respond.

Sources: [7] [5] [1]

Ongoing access is documented; clinical responsiveness is not

The semaglutide page says every plan includes ongoing provider access and a support community. It also uses the heading “24/7 Provider Support,” but the accompanying explanation describes a customer-support team available around the clock. That does not establish round-the-clock access to a physician or another prescribing clinician. The public pages do not specify a routine follow-up frequency, continuing clinical response time or a consistent schedule for reviewing tolerance and response before subsequent prescriptions.

The Spanish-language help center provides call or text contact at (307) 405-1638. It directs medical questions to the portal’s Talk to the Doctor function and billing or technical matters to support@coreagerx.com. These are useful, differentiated contact paths, although a Spanish help center does not confirm Spanish-language clinical care. Patients should establish how to reach their treating team, rather than assuming that an administrative support response is equivalent to clinical assessment or prescribing advice.

NIDDK describes medication follow-up in terms of benefits, side effects and response, not merely continued payment. FDA also reports measurement and administration errors involving compounded GLP-1 medicines, including some associated with hospitalization; unclear instructions belong with the prescriber or pharmacist, not a calculation based on a review. These concerns make clinical follow-up beyond renewal notices a useful standard for questions. The available pages document access, but not how consistently that access delivers ongoing clinical review.

Sources: [13] [14] [2] [1]

Questions & answers

Is CoreAge Rx itself the medical practice?

Its legal footer says no. CoreAgeRx provides technology and administrative coordination, while three named independent professional entities handle evaluations, treatment planning and prescribing. Ask which entity and clinician will be responsible for your care; the brand name alone does not identify the treating professional.

Sources: [11]

Does the $79 semaglutide offer establish my total bill?

No. It is an advertised starting monthly price, with same-price dosing, supplies and free shipping promoted. The documentation does not establish the quantity, presentation or conditions needed for that minimum. Obtain the actual order total and confirm whether any consultation fee can remain payable if treatment is declined.

Sources: [11] [5]

Will I receive a full refund if I am not approved?

The public statements disagree. The FAQ promises an automatic 100% refund, but the refund policy says an applicable $50–$100 provider consultation fee is nonrefundable. Ask for the exact terms governing your purchase before paying. The policy’s processing estimate also allows additional time for the bank to display an approved refund.

Sources: [7] [5]

Can I use my usual pharmacy?

That remains unresolved in the public documentation. The FAQ requires the affiliated network, while the terms permit requesting your own pharmacy by emailing support before completing the order. Confirm availability for the exact prescription, whether the package price changes, and which pharmacy will actually prepare and dispense it.

Sources: [7] [12]

Does CoreAge Rx accept insurance or serve every state?

The FAQ says it does not accept insurance and serves only the United States, with state restrictions depending on therapy and medication. Availability is confirmed during intake rather than established by a complete public state list. Its terms separately restrict submission of telemedicine-service claims to government and private payers.

Sources: [7] [12]

Does “microdosing” mean the offering has proven longevity benefits?

No such conclusion follows from the consulted evidence. CoreAge Rx markets semaglutide and tirzepatide microdosing offerings, but commercial descriptions do not establish clinical efficacy for those protocols. Published trial outcomes cannot be transferred to a provider’s microdoses, compounded preparations or vitamin blends, and do not predict an individual result.

Sources: [8] [9] [3] [4]

Our assessment

CoreAge Rx documents a recognizable telehealth pathway: online intake, independent clinical decision-making, pharmacy fulfillment, included standard shipping and ongoing provider access. Its acknowledgment that compounded semaglutide is not FDA approved is a meaningful disclosure. However, the public record does not establish provider-specific treatment outcomes, validate microdosing claims or independently verify clinicians and pharmacies. More immediately, contradictory refund, charge-timing, renewal and pharmacy-choice statements prevent a confident reading of the purchase terms. A reasonable next step is written clarification of the exact product, dispensing pharmacy, initial charge, recurring authorization, nonrefundable fees and clinical follow-up arrangements before payment. The evidence supports describing CoreAge Rx’s advertised service—not endorsing its clinical performance or assuming the most favorable commercial statement will govern.

Visit CoreAge Rx’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

CoreAge Rx Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

At a glance

01Start with the product, not the trial headline

02Who actually provides the medical care?

03What the advertised monthly prices establish

04Intake is a clinical review, not an approval guarantee

05The pharmacy and formulation remain order-specific

06Refund and renewal language needs reconciliation

07Delivery estimates do not establish cold-chain performance

08Ongoing access is documented; clinical responsiveness is not